545 related articles for article (PubMed ID: 30130255)
21. Siglec-9 Regulates an Effector Memory CD8
Haas Q; Boligan KF; Jandus C; Schneider C; Simillion C; Stanczak MA; Haubitz M; Seyed Jafari SM; Zippelius A; Baerlocher GM; Läubli H; Hunger RE; Romero P; Simon HU; von Gunten S
Cancer Immunol Res; 2019 May; 7(5):707-718. PubMed ID: 30988027
[TBL] [Abstract][Full Text] [Related]
22. Gene conversions are frequent but not under positive selection in the Siglec gene families of primates.
Zid M; Drouin G
Genome; 2014 Jun; 57(6):317-25. PubMed ID: 25166301
[TBL] [Abstract][Full Text] [Related]
23. The sialoglycan-Siglec-E checkpoint axis in dexamethasone-induced immune subversion in glioma-microglia transwell co-culture system.
Wielgat P; Czarnomysy R; Trofimiuk E; Car H
Immunol Res; 2019 Oct; 67(4-5):348-357. PubMed ID: 31741237
[TBL] [Abstract][Full Text] [Related]
24. Sialic Acid Mimetics to Target the Sialic Acid-Siglec Axis.
Büll C; Heise T; Adema GJ; Boltje TJ
Trends Biochem Sci; 2016 Jun; 41(6):519-531. PubMed ID: 27085506
[TBL] [Abstract][Full Text] [Related]
25. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
Boelaars K; van Kooyk Y
Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
[TBL] [Abstract][Full Text] [Related]
26. Sensing the neuronal glycocalyx by glial sialic acid binding immunoglobulin-like lectins.
Linnartz-Gerlach B; Mathews M; Neumann H
Neuroscience; 2014 Sep; 275():113-24. PubMed ID: 24924144
[TBL] [Abstract][Full Text] [Related]
27. Constitutively expressed Siglec-9 inhibits LPS-induced CCR7, but enhances IL-4-induced CD200R expression in human macrophages.
Higuchi H; Shoji T; Iijima S; Nishijima K
Biosci Biotechnol Biochem; 2016 Jun; 80(6):1141-8. PubMed ID: 26923638
[TBL] [Abstract][Full Text] [Related]
28. Studies on the Detection, Expression, Glycosylation, Dimerization, and Ligand Binding Properties of Mouse Siglec-E.
Siddiqui S; Schwarz F; Springer S; Khedri Z; Yu H; Deng L; Verhagen A; Naito-Matsui Y; Jiang W; Kim D; Zhou J; Ding B; Chen X; Varki N; Varki A
J Biol Chem; 2017 Jan; 292(3):1029-1037. PubMed ID: 27920204
[TBL] [Abstract][Full Text] [Related]
29. Discovery and expression of 3 siglecs-like in Oreochromis niloticus neutrophil, and their interaction with group B streptococcal sialylated capsular polysaccharides.
Dong J; Wei Y; Ye X; Sun C; Tian Y; Lu M; Du J; Chen Z
Mol Immunol; 2016 May; 73():158-69. PubMed ID: 26847490
[TBL] [Abstract][Full Text] [Related]
30. Sialylation pattern in lung epithelial cell line and Siglecs expression in monocytic THP-1 cells as cellular indicators of cigarette smoke - induced pathology in vitro.
Wielgat P; Trofimiuk E; Czarnomysy R; Holownia A; Braszko JJ
Exp Lung Res; 2018 Apr; 44(3):167-177. PubMed ID: 29781747
[TBL] [Abstract][Full Text] [Related]
31. Assessment of sialic acid diversity in cancer- and non-cancer related CA125 antigen using sialic acid-binding Ig-like lectins (Siglecs).
Mitic N; Milutinovic B; Jankovic M
Dis Markers; 2012; 32(3):187-94. PubMed ID: 22377735
[TBL] [Abstract][Full Text] [Related]
32. Siglec-7 expression is reduced on a natural killer (NK) cell subset of obese humans.
Rosenstock P; Horstkorte R; Gnanapragassam VS; Harth J; Kielstein H
Immunol Res; 2017 Oct; 65(5):1017-1024. PubMed ID: 28786023
[TBL] [Abstract][Full Text] [Related]
33. MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint.
Smith BAH; Deutzmann A; Correa KM; Delaveris CS; Dhanasekaran R; Dove CG; Sullivan DK; Wisnovsky S; Stark JC; Pluvinage JV; Swaminathan S; Riley NM; Rajan A; Majeti R; Felsher DW; Bertozzi CR
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2215376120. PubMed ID: 36897988
[TBL] [Abstract][Full Text] [Related]
34. Tools to study and target the Siglec-sialic acid axis in cancer.
Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
[TBL] [Abstract][Full Text] [Related]
35. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
Daly J; Carlsten M; O'Dwyer M
Front Immunol; 2019; 10():1047. PubMed ID: 31143186
[TBL] [Abstract][Full Text] [Related]
36. Impact of Siglecs on autoimmune diseases.
Brzezicka KA; Paulson JC
Mol Aspects Med; 2023 Apr; 90():101140. PubMed ID: 36055802
[TBL] [Abstract][Full Text] [Related]
37. Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells.
Lock K; Zhang J; Lu J; Lee SH; Crocker PR
Immunobiology; 2004; 209(1-2):199-207. PubMed ID: 15481154
[TBL] [Abstract][Full Text] [Related]
38. Siglecs: A journey through the evolution of sialic acid-binding immunoglobulin-type lectins.
Bornhöfft KF; Goldammer T; Rebl A; Galuska SP
Dev Comp Immunol; 2018 Sep; 86():219-231. PubMed ID: 29751010
[TBL] [Abstract][Full Text] [Related]
39. Siglec receptors as new immune checkpoints in cancer.
Stanczak MA; Läubli H
Mol Aspects Med; 2023 Apr; 90():101112. PubMed ID: 35948467
[TBL] [Abstract][Full Text] [Related]
40. Siglec and anti-Siglec therapies.
Murugesan G; Weigle B; Crocker PR
Curr Opin Chem Biol; 2021 Jun; 62():34-42. PubMed ID: 33607404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
